Aurobindo Pharma Anakapalli facility gets 4 USFDA observations
Advertisement
Hyderabad: Aurobindo Pharma has announced that the company has received four observations from the United States Food and Drug Administration (US FDA) after the inspection at the Company’s Unit XIV, an API Non-antibiotic Manufacturing facility situated at Paravada Industrial Area, Anakapalli District, Andhra Pradesh.
The inspection was held from 15th May to 19th May 2023.
"At the end of the inspection, we have been issued a ‘Form 483’ with Four observations. The observations are procedural in nature." the company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.